References
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, and Després J-P, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–e596.
- Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, Barker-Collo S, Moran AE, Sacco RL, Truelsen T, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study. Neuroepidemiology. 2015;45(3):161–76.doi:https://doi.org/10.1159/000441085.
- Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.doi:https://doi.org/10.1161/STR.0000000000000024.
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–e418.
- Wu MY, Yiang GT, Liao WT, Tsai A-Y, Cheng Y-L, Cheng P-W, Li C-Y, and Li C-J. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46:1650–67.
- Sarraj A, Pizzo E, Lobotesis K, Abraham MG, Blackburn S, Day AL, Hicks W, Vora NA, Budzik RF, Sharrief AZ, et al. Endovascular thrombectomy in patients with large core ischemic stroke: a cost-effectiveness analysis from the SELECT study. J Neurointerv Surg 2020;13:875–882.
- Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.doi:https://doi.org/10.1056/NEJMoa1713973.
- Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.doi:https://doi.org/10.1056/NEJMoa1706442.
- Nour M, Scalzo F, and Liebeskind DS. Ischemia-reperfusion injury in stroke. Interv Neurol. 2013;1:185–99.doi:https://doi.org/10.1159/000353125.
- Mandalaneni K, Rayi A, and Jillella DV. Stroke reperfusion injury. Treasure Island (FL): StatPearls; 2021.
- Aguzzi A, Barres BA, and Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156–61.doi:https://doi.org/10.1126/science.1227901.
- Cherry JD, Olschowka JA, and O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11(1):98.doi:https://doi.org/10.1186/1742-2094-11-98.
- Tang Y and Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–94.doi:https://doi.org/10.1007/s12035-014-9070-5.
- Jayaraj RL, Azimullah S, Beiram R, Jalal FY, and Rosenberg GA. Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019;16:142.doi:https://doi.org/10.1186/s12974-019-1516-2.
- Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles, FR, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 2004;12(14):3871–83.doi:https://doi.org/10.1016/j.bmc.2004.05.006.
- Rao G, Houson H, Nkepang G, Yari H, Teng C, and Awasthi V. Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G318–G327.doi:https://doi.org/10.1152/ajpgi.00066.2018.
- Rao G, Xie J, Hedrick A, and Awasthi V. Hemorrhagic shock-induced cerebral bioenergetic imbalance is corrected by pharmacologic treatment with EF24 in a rat model. Neuropharmacology. 2015;99:318–27.doi:https://doi.org/10.1016/j.neuropharm.2015.07.033.
- Yadav VR, Hussain A, Sahoo K, and Awasthi V. Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA. J Pharmacol Exp Ther. 2014;351(2):413–22.doi:https://doi.org/10.1124/jpet.114.217331.
- Yadav VR, Hussain A, Xie J, Kosanke S, and Awasthi V. The salutary effects of diphenyldifluoroketone EF24 in liver of a rat hemorrhagic shock model. Scand J Trauma Resusc Emerg Med. 2015;23(1):8.doi:https://doi.org/10.1186/s13049-015-0098-y.
- Yadav VR, Sahoo K, Roberts PR, and Awasthi V. Pharmacologic suppression of inflammation by a diphenyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival. J Pharmacol Exp Ther. 2013;347(2):346–56.doi:https://doi.org/10.1124/jpet.113.208009.
- Yadav VR, Vilekar P, Awasthi S, and Awasthi V. Hemorrhage-induced interleukin-1 receptor pathway in lung is suppressed by 3,5-bis(2-fluorobenzylidene)-4-piperidone in a rat model of hypovolemic shock. Artif Organs. 2014;38(8):675–83.doi:https://doi.org/10.1111/aor.12305.
- Awasthi V, Vilekar P, Rao G, and Awasthi S. Anti-inflammatory mediators ST2 and SIGIRR are induced by diphenyldifluoroketone EF24 in lipopolysaccharide-stimulated dendritic cells. Immunobiology. 2020;225(2):151886.doi:https://doi.org/10.1016/j.imbio.2019.11.021.
- Vilekar P, Awasthi S, Natarajan A, Anant S, and Awasthi V. EF24 suppresses maturation and inflammatory response in dendritic cells. Int Immunol. 2012;24(7):455–64.doi:https://doi.org/10.1093/intimm/dxr121.
- Vilekar P, Rao G, Awasthi S, and Awasthi V. Diphenyldifluoroketone EF24 suppresses pro-inflammatory interleukin-1 receptor 1 and toll-like receptor 4 in lipopolysaccharide-stimulated dendritic cells. J Inflamm (Lond). 2015;12(1):55.doi:https://doi.org/10.1186/s12950-015-0096-x.
- Kasinski AL, Du Y, Thomas SL, Zhao J, Sun S-Y, Khuri FR, Wang C-Y, Shoji M, Sun A, Snyder JP, et al. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol. 2008;74:654–61.
- Rao G, Nkepang G, Xu J, Yari H, Houson H, Teng C, and Awasthi V. Ubiquitin receptor RPN13 mediates the inhibitory interaction of diphenyldihaloketones CLEFMA and EF24 With the 26S proteasome. Front Chem. 2018;6:392.
- Wojcik C and Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke. 2004;35(6):1506–18.doi:https://doi.org/10.1161/01.STR.0000126891.93919.4e.
- Mdzinarishvili A, Geldenhuys WJ, Abbruscato TJ, Bickel U, Klein J, and Van der Schyf CJ. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci Lett. 2005;383:49–53.doi:https://doi.org/10.1016/j.neulet.2005.03.042.
- Houson H, Mdzinarishvili A, Gali H, Sidorov E, and Awasthi V. PET detection of cerebral necrosis using an infarct-avid agent 2-deoxy-2-[(18)F]fluoro-D-glucaric acid (FGA) in a mouse model of the brain stroke. Mol Imaging Biol. 2020;22(5):1353–61.doi:https://doi.org/10.1007/s11307-020-01513-9.
- Saver JL. Time is brain–quantified. Stroke. 2006;37:263–66.doi:https://doi.org/10.1161/01.STR.0000196957.55928.ab.
- Sarraj A, Hassan AE, Savitz S, Sitton C, Grotta J, Chen P, Cai C, Cutter G, Imam B, et al. Outcomes of endovascular thrombectomy vs medical management alone in patients with large ischemic cores: a secondary analysis of the optimizing patient’s selection for endovascular treatment in acute ischemic stroke (SELECT) study. JAMA Neurol. 2019;76(10):1147.doi:https://doi.org/10.1001/jamaneurol.2019.2109.
- Sarraj A, Hassan AE, Grotta J, Blackburn S, Day A, Abraham M, Sitton C, Dannenbaum M, Cai C, Pujara D, et al. Early infarct growth rate correlation with endovascular thrombectomy clinical outcomes: analysis from the SELECT study. Stroke. 2021;52(1):57–69.doi:https://doi.org/10.1161/STROKEAHA.120.030912.
- Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, and Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology. 2009;56:329–41.doi:https://doi.org/10.1016/j.neuropharm.2008.10.006.
- Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222–29. doi:https://doi.org/10.1159/000069318.
- Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11:1753–63.doi:https://doi.org/10.1517/14656566.2010.493558.
- Alvarez-Sabin J and Roman GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013;3:1395–414.doi:https://doi.org/10.3390/brainsci3031395.
- Saver JL, Starkman S, Eckstein M, Stratton SJ, Pratt FD, Hamilton S, Conwit R, Liebeskind DS, Sung G, Kramer I, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372:528–36.
- Kallio PJ, Wilson WJ, O’Brien S, Makino Y, and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem. 1999;274:6519–25.doi:https://doi.org/10.1074/jbc.274.10.6519.
- Villeneuve NF, Lau A, and Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal. 2010;13:1699–712.doi:https://doi.org/10.1089/ars.2010.3211.
- Love IM, Shi D, and Grossman SR. p53 ubiquitination and proteasomal degradation. Methods Mol Biol. 2013;962:63–73.
- Kanarek N and Ben-Neriah Y. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev. 2012; 246:77–94. doi:https://doi.org/10.1111/j.1600-065X.2012.01098.x.
- Williams AJ, Dave JR, and Tortella FC. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int. 2006;49:106–12.doi:https://doi.org/10.1016/j.neuint.2006.03.018.
- Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, and Tortella FC. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab. 2003;23:75–87.
- Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr K-M, Aarseth J, and Vedeler CA . IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005;111(6):360–65.doi:https://doi.org/10.1111/j.1600-0404.2005.00416.x.
- Gandolfi M, Smania N, Vella A, Picelli A, and Chirumbolo S. Assessed and emerging biomarkers in stroke and training-mediated stroke recovery: state of the art. Neural Plast. 2017;2017:1389475.doi:https://doi.org/10.1155/2017/1389475.
- Li P, Mao L, Zhou G, Leak RK, Sun B-L, Chen J, and Hu X. Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. Stroke. 2013;44(12):3509–15.doi:https://doi.org/10.1161/STROKEAHA.113.002637.
- Lindvall O and Kokaia Z. Neurogenesis following stroke affecting the adult brain. Cold Spring Harb Perspect Biol. 2015;7(11):a019034.doi:https://doi.org/10.1101/cshperspect.a019034.
- Hayashi T, Noshita N, Sugawara T, and Chan PH. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J Cereb Blood Flow Metab. 2003;23:166–80.doi:https://doi.org/10.1097/01.WCB.0000041283.53351.CB.
- Lee SH, Lee YJ, and Han HJ. Effect of arachidonic acid on hypoxia-induced IL-6 production in mouse ES cells: involvement of MAPKs, NF-kappaB, and HIF-1alpha. J Cell Physiol. 2010;222:574–85.doi:https://doi.org/10.1002/jcp.21973.
- Lee SH, Kim MH, and Han HJ. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol. 2009;297:C207–216.doi:https://doi.org/10.1152/ajpcell.00579.2008.
- Krupinski J, Kaluza J, Kumar P, Kumar S, and Wang JM. Some remarks on the growth-rate and angiogenesis of microvessels in ischemic stroke. Morphometric and immunocytochemical studies. Patol Pol. 1993;44:203–09.
- Krupinski J, Kaluza J, Kumar P, Kumar S, and Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994;25:1794–98.doi:https://doi.org/10.1161/01.STR.25.9.1794.
- Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, and Kaluza J. A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke. 1997;28(3):564–73.doi:https://doi.org/10.1161/01.STR.28.3.564.
- Buga AM, Margaritescu C, Scholz CJ, Radu E, Zelenak C, and Popa-Wagner A. Transcriptomics of post-stroke angiogenesis in the aged brain. Front Aging Neurosci. 2014;6:44.doi:https://doi.org/10.3389/fnagi.2014.00044.
- He Y, Li W, Hu G, Sun H, and Kong Q. Bioactivities of EF24, a novel curcumin analog: a review. Front Oncol. 2018;8:614.doi:https://doi.org/10.3389/fonc.2018.00614.
- Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res. 2008;68(6):1962–69.doi:https://doi.org/10.1158/0008-5472.CAN-07-6011.